Category: 3. Business

MP Materials (MP) shares moved higher after the company reported annual net income growth and strong revenue gains. Investors are paying close attention to profitability trends, as rare earth demand shapes the outlook for the sector.

See our latest analysis for MP Materials.

After a strong annual report, MP Materials’ share price showed impressive momentum with a 12.09% jump over the past week, bringing its latest close to $61.95. While the 1-year total shareholder return sits at a remarkable 194.02%, longer-term results also remain well ahead of the market. This signals building optimism around the business’s growth prospects and sector position.

If the recent shift in momentum has you curious about what else is out there, now is the perfect moment to broaden the search and discover fast growing stocks with high insider ownership

With MP Materials trading at a notable premium to its recent historical levels, investors are left to wonder if this surge is a signal that more upside remains, or if the market has already priced in all the future growth.

With the current fair value pegged at $79.11 and the latest close at $61.95, the prevailing narrative suggests there is meaningful upside left. Let us look at a core catalyst that drives this bold view.

Structural global shifts prioritizing domestic and allied supply chains for critical materials, underpinned by national security and electrification policies, have resulted in massive government funding, ownership stakes, and market protections for MP. This sets up long-term demand and premium pricing for U.S.-produced rare earths and supports sustained margin expansion.

Read the complete narrative.

Why do analysts see room to run? Their price target calculation leans on blockbuster revenue projections, robust margin signals, and the premium that policymakers and major tech buyers are willing to pay for strategic materials security. Want to see the specific figures driving this powerful upside case? The full narrative pulls back the curtain.

Result: Fair Value of $79.11 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, ambitious facility build-outs risk delays or cost overruns. In addition, heavy dependence on a few key customers could introduce earnings volatility ahead.

Find out about the key risks to this MP Materials narrative.

Taking a different look using the price-to-sales ratio, MP Materials trades at 47.2x, which is much higher than both its peer average of 0.8x and the US Metals and Mining industry average of 2.4x. Even compared to a fair ratio of 2.5x, the stock appears expensive. Does this large gap signal added risk for new investors?

See what the numbers say about this price — find out in our valuation breakdown.

If you have your own perspective, or want to dive into the details yourself, it takes just minutes to craft an independent narrative. Do it your way

A great starting point for your MP Materials research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Smart investors consistently seek fresh opportunities to get ahead of the market. Don’t miss your chance to tap into stocks with hidden potential using these handpicked screeners from Simply Wall Street:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MP.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Artificial intelligence (AI) allows computers and machines to simulate learning, comprehending, problem-solving, and decision-making in a similar manner to humans.¹ AI is rapidly transforming the field of pharmacy and will continue to do so.

The benefits of AI in pharmacy are far-reaching. It can enhance clinical and personalized medicine through pharmacogenomics, clinical decision support systems, and predictive analytics for medication management. It can streamline pharmacy operations through workflow automation, inventory optimization, billing, and regulatory compliance. AI improves patient safety and engagement by way of adverse event monitoring, patient engagement tools, and educational resources. It also accelerates drug discovery and development through clinical trial optimization and drug repurposing.

Although these benefits are crucial to the field of pharmacy, integration of AI presents significant ethical challenges that must be recognized and addressed to ensure patient welfare. Careful consideration must be given to key ethical concerns such as data privacy, algorithmic bias, transparency, accountability, and human oversight in order to balance crucial innovation with ethical standards.

Data Privacy and Security

AI relies on vast amounts of sensitive patient data, thereby creating significant data privacy challenges. Proper safeguards are necessary to protect patient data and adhere to relevant regulatory requirements, such as the Health Insurance Portability and Accountability Act (HIPAA).²

Data Breaches and Cyber-Attacks

AI-driven pharmacies are vulnerable to data breaches and cyber-attacks through the targeting of patient information, intellectual property, and drug data. An increased reliance on digital systems creates entry points for attackers to use ransomware, commence phishing, and breach AI data pipelines.³

Re-Identification of De-Identified Data

Combining datasets using advanced algorithms to exploit unique combinations of identifiers that can then be used to find overlapping information. These can then be pieced together to uncover a real identity.⁴

Third-Party Vendor Risk

In health care, almost one-third of all data breaches originate through third-party compromise. These attacks target vulnerabilities in the vendor’s systems, allowing attackers to access data they normally would not have access to.⁵

Algorithmic Bias and Fairness

Most AI algorithms learn from enormous datasets. If these datasets are incomplete, skewed, or compromised in any way, the AI algorithm may reproduce and amplify incorrect information.

Biased Training Data

If training data is misrepresentative of the full population, AI may propagate this bias, which may lead to poor patient outcomes.⁶

Lack of Data Diversity

Data diversity represents the inclusion of data from a variety of demographics including age, gender, ethnicity, geographic locations, and socioeconomic status. Cultural diversity indicates accounting for differences in language, customs, and mores. Behavioral diversity denotes including data from more than just dominant patterns. Finally, contextual diversity means that data is captured from varied environments and situations.⁶

Information Bias

Information bias is the outcome of a combination of errors in how training data is collected, measured, or processed that can lead to inaccurate and possibly discriminatory results.

Unintended Feedback Bias

AI models learn not only through large datasets but also through a feedback loop. This can lead AI to reinforce its own flawed conclusions.

Transparency and Explainability

By making AI processes and data understandable and providing clear and understandable reasoning for recommendations produced by AI, pharmacists can help detect bias, ensure accuracy, and enhance patient safety. This also facilitates shared decision-making by helping both patients and health care providers understand the risks and benefits of therapy.

Human Oversight and Control

Incorporating human intervention throughout the AI process is imperative to ensure patient safety, ethical practice, regulatory compliance, and system accuracy. AI cannot match pharmacists’ strategic thinking, ethical judgment, or clinical expertise. Regulators of AI must focus on human-in-the-loop (intervention at critical points to guide and review AI outputs) and human-on-the-loop (human supervision for necessary interventions).⁷

Equitable Access

Health equity relating to AI applications refers to the fair and just distribution of health technologies and their associated benefits. All individuals should have access to the same health care services regardless of race, gender, ethnicity, socioeconomic status, or geographic location.

Artificial intelligence must advance health care and provide positive health outcomes while also doing so in a way that lessens existing health disparities rather than increasing them.⁸

Accountability and Liability

Accountability and liability in pharmacy when using AI is complex as there are several stakeholders to consider and a lack of clear legal frameworks.

• Pharmacists: Pharmacists are responsible for patient care and are required to act under the “reasonable professional” standard whether they are using AI as a tool. Failure to act on a flawed AI recommendation can result in liability and, conversely, failure to use an available AI tool that may have prevented an error are liable as well.
• Health care institutions: Hospitals and pharmacies can be held liable for the AI they implement. Negligent supervision encompasses failure to adequately train staff and set oversight procedures. Negligent selections would be implementing an unreliable and/or unverified AI system. Vicarious liability includes holding the institution responsible for the actions of their employees.
• AI developers and vendors: Product liabilities include coding errors and glitches, inadequate prerelease testing, failure to warn of limitations and risks of products, and using biased training data that leads to discriminatory outcomes.

Patient Autonomy and Informed Consent

Patients must understand how AI can influence treatment decisions through clear communication about the process in which AI analyzes data and makes recommendations. Patients have the absolute right to make informed decisions about their care, even when AI is involved.

Regular Monitoring and Auditing

To remain reliable and effective, AI systems must be continuously monitored and evaluated for “drift”, where the accuracy of AI recommendations degrades over time due to data changes or evolving circumstances.

Conclusion

The potential for AI to transform the field of pharmacy is immense. This potential is tempered by a wide range of ethical considerations including data privacy, bias, transparency, equitable access, and accountability. Successful implementation of AI requires collaborative efforts between AI developers, pharmacists, regulators, and more to establish ethical standards and educational frameworks.

REFERENCES

1. What is AI? IBM website. August 9, 2024. https://www.ibm.com/think/topics/artificial-intelligence. Accessed September 9, 2025.

2. Artificial Intelligence in Pharmacy: Appropriate Use of AI (Part 1 of 2). Florida Pharmacy Foundation website. https://flpharmfound.org/artificial-intelligence-in-pharmacy-part-1#:~:text=Additionally%2C%20the%20ethical%20implications%20of,and%20mitigate%20potential%20ethical%20issues. Accessed September 9, 2025.

3. Li J. Security Implications of AI Chatbots in Health Care. J Med Internet Res. 2023 Nov 28;25:e47551. doi: 10.2196/47551. PMID: 38015597; PMCID: PMC10716748.

4. Erosion of Anonymity: Mitigating the Risk of Re-Identification of De-Identified Health Data. Health Law Advisor website. February 28, 2019. https://www.healthlawadvisor.com/erosion-of-anonymity-mitigating-the-risk-of-re-identification-of-de-identified-health-data#:~:text=To%20mitigate%20these%20risks%2C%20organizations%20can:%20*,sharing%20and%20use%20agreement%20with%20the%20recipient. Accessed September 10, 2025.

5. More Than One-Third of Data Breaches Due to Third-Party Supplier Compromises. The HIPAA Journal website. March 28, 2025. https://www.hipaajournal.com/more-than-one-third-data-breaches-third-party-compromises/. Accessed September 10, 2025.

6. Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A. Addressing bias in big data and AI for health care: A call for open science. Patterns (N Y). 2021 Oct 8;2(10):100347. doi: 10.1016/j.patter.2021.100347. PMID: 34693373; PMCID: PMC8515002.

7. Singh R, Paxton M, Auclair J. Regulating the AI-enabled ecosystem for human therapeutics. Commun Med (Lond). 2025 May 17;5(1):181. doi: 10.1038/s43856-025-00910-x. PMID: 40382515; PMCID: PMC12085592.

8. Health Equity and Ethical Considerations in Using Artificial Intelligence in Public Health and Medicine. Centers for Disease Control and Prevention website. August 22, 2024. https://www.cdc.gov/pcd/issues/2024/24_0245.htm#:~:text=The%20potential%20of%20AI%20to,or%20geographic%20location%20(8). Accessed September 10, 2025.

RWE (XTRA:RWE) stock has been on the move lately, and many investors are keeping an eye on the utility’s performance across European and international markets. The company’s ability to generate consistent revenue growth makes it a key name to watch in the sector.

See our latest analysis for RWE.

RWE’s steady run has caught the eye lately, especially after a robust rally that’s seen the share price jump nearly 48% year-to-date and surge over 27% in the last 90 days. Momentum is clearly building, with the one-year total shareholder return also standing strong at 41.8%, highlighting both recent excitement and solid long-term value for investors.

If you want to broaden your perspective beyond utilities, now’s a great time to discover fast growing stocks with high insider ownership

With RWE’s impressive rally and steady fundamentals, investors are left to wonder if the recent gains signal a bargain waiting to be seized or if the market has already taken the company’s future growth prospects into account.

With RWE shares last closing at €43.74 and the most-watched narrative suggesting a fair value of €47.16, there is a visible gap between current price and what analysts believe is justified. This difference is drawing fresh attention from market observers, and the stage is set for a closer look at the catalysts shaping those projections.

Major policy tailwinds in core markets, the U.K. retention of a single price zone, extension of CfD periods to 20 years, higher auction price caps, and the new U.S. “Big Beautiful Bill” with tax incentives are expected to provide greater revenue visibility and de-risk project cash flows. These factors may support higher recurring revenues and improved earnings quality over time.

Read the complete narrative.

Curious what aggressive financial forecasts are behind that premium? The narrative is anchored in bold growth drivers and a future multiple that is turning heads. Don’t miss the surprisingly optimistic projections that could change how you value RWE.

Result: Fair Value of €47.16 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, unpredictably weak wind conditions or supply chain disruptions could quickly challenge RWE’s current growth outlook and prompt investors to reassess their expectations.

Find out about the key risks to this RWE narrative.

Taking a different approach, our DCF model estimates RWE’s fair value at €26.80, which is significantly lower than the current share price. This means that, despite the optimism shown by analyst targets, a cash flow-based perspective sees the stock as overvalued. Is the market too optimistic about RWE’s growth, or is the DCF being too cautious?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out RWE for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 920 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

If you want a second opinion or enjoy digging into the numbers yourself, it takes less than three minutes to build your own perspective and Do it your way.

A great starting point for your RWE research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Upgrade your portfolio by taking action on fresh opportunities you may be overlooking. These screens are waiting for you and could reveal your next winning stock.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RWE.DE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

China’s jewellery retailers are reeling from gold’s blistering rally and the reduction of a tax rebate as high prices have deterred buyers and led to hundreds of store closures in one of the world’s largest consumer markets for the metal.

Large retail chains have reduced their footprint in mainland China this year, while a number of small sellers told the Financial Times that rising prices and a growing tax burden had torpedoed sales.

The price of gold has jumped by half this year to more than $4,000 a troy ounce as investors pile into the asset as a hedge against geopolitical uncertainty, growing levels of global government debt and concerns over a falling dollar.

In China, where gold jewellery is traditionally purchased as a wedding gift or as a store of value, high prices for the commodity have run up against weak consumer sentiment amid slowing economic growth.

Retailers are also adapting to new rules introduced this month that increase taxes on gold jewellery purchases by cutting a long-standing rebate. The higher tax burden has pushed sellers to raise prices further, they said.

“This industry is quite difficult at the moment, especially after the tax increase,” said Fifi Zheng, who helps run Aiyisheng, her family’s business based in Shenzhen’s gold trading district Shuibei. “Lots of Chinese consumers aren’t buying, so it’s quite hard to accept [the tax], even though it only adds a couple dozen renminbi per gramme.”

While gold purchases for weddings were holding up, everyday purchases had “fallen maybe 40 to 50 per cent” since the new rules were introduced, she added.

Chow Tai Fook, China’s biggest jewellery retailer by sales, has closed about 1,000 mainland stores this year, a reduction of 15 per cent. The company on Tuesday reported net profit of HK$2.5bn (US$320mn) in the half-year to the end of September, unchanged from a year earlier, on HK$39bn of revenue, its lowest in five years.

Chow Tai Fook managing director Kent Wong said in an earnings presentation that the company had closed underperforming stores as part of a shift away from lower-tier to more affluent cities, which were experiencing a “better recovery in consumer demand”.

Over the past year, rival operator Lukfook has closed more than 200 mainland stores, reducing its total store count since the start of the year by 7 per cent. The company on Thursday said half-year revenue to the end of September increased 26 per cent to HK$6.8bn compared with the same period last year, while net profit rose by 42.5 per cent to HK$619mn.

Lukfook said: “Despite the high gold prices, the retailing business in the mainland market showed continued improvement.” It added that it was still evaluating implications of the tax policy change.

Carlton Lai, an analyst at Daiwa Capital Markets, said the store closures followed a period of overexpansion during Covid-19 when spending was more robust.

“As consumption slowed, the productivity of these stores declined significantly,” he said, adding that the issue was compounded by growing competition from newer brands and surging gold prices.

In Shuibei — where thousands of shops crammed into multistorey malls handle transactions equal to 70 per cent of the Shanghai Gold Exchange’s annual deliveries of the metal, according to state media — sellers were dour. Many complained the new tax had come at the wrong time.

“Our prices were already high and now they’re higher after the tax,” said Chen, a Shuibei seller who declined to give her full name. “If [customers] want to get married, there’s no other choice: they just buy less.”

Daiwa’s Lai said the tax change aimed to curb speculative purchases of gold jewellery and could push low-quality retailers out of the market.

They could also reduce unregulated over-the-counter transactions in favour of trading through the Shanghai Gold Exchange and close tax refund loopholes, he said.

While jewellery sellers are struggling, demand for gold investment products has risen as retail traders search for ways to gain exposure to the metal. The new tax rules do not apply to investment products.

Holdings of domestic gold exchange traded funds increased 164 per cent to 194 tonnes in the first three quarters of this year, according to the China Gold Association.

“The panic caused for people in the industry by this tax policy hasn’t yet subsided,” said Li Zhaofen, a Shuibei retailer and wholesaler. “This is because gold has been tax free for the past 20 years . . . the future direction remains unclear.”

Additional reporting by Haohsiang Ko in Hong Kong

The two sides had been in a standoff over the implementation of the West African country’s new mining code that gave Mali a bigger share of revenue from gold miners as gold prices surged to a record high.

Sign up here.

The agreement included Mali releasing the four employees from prison, where they had been held since November 2024, according to a statement from the company.

The sources who confirmed the release asked not to be named because they were not authorised to discuss the matter.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

The meeting of OPEC+, which pumps half of the world’s oil, comes as oil prices are also under pressure from the prospect of a Russia-Ukraine peace deal. Brent crude closed on Friday near $63 a barrel, down 15% this year.

Sign up here.

OPEC+, which groups the Organization of the Petroleum Exporting Countries and allies led by Russia, pumps about half the world’s oil and has been discussing for years production capacity figures against which members’ output targets are set.

In a separate meeting on Sunday, the full OPEC+ group is expected to agree on a mechanism to assess members’ maximum production capacity, sources told Reuters this week. OPEC said in May this capacity assessment would be used as a reference for 2027 output baselines.

A series of online meetings is scheduled to begin at 1300 GMT on Sunday. OPEC+ ministers are also expected to not make any changes to group-wide production targets for 2026, other sources said this week.

OPEC+ had been curtailing supplies for years until April when the eight members began to raise production to recover market share. The cuts had peaked in March, amounting to 5.85 million barrels per day, almost 6% of world output, in total.

The eight – Saudi Arabia, Russia, UAE, Kazakhstan, Kuwait, Iraq, Algeria and Oman – have raised output targets by around 2.9 million bpd from April to December.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

ScotRail has announced its Christmas and New Year timetable which includes the last Christmas Eve and Hogmanay trains departing earlier than usual.

On Boxing Day, new services will run between Aberdeen and Edinburgh Waverley, as well as between Arbroath and Edinburgh Waverley.

Extra services and more seats will be added across the country in the run-up to Christmas, with additional late-night weekend services on key routes, alongside longer trains.

Essential work will be carried out on lines over the festive period so ScotRail is asking customers to plan ahead.

On Christmas Eve services will run as normal until about 19:00 when services will begin to wind down.

As in previous years, no trains will run on Christmas Day and New Year’s Day.

On Boxing Day there will be a revised timetable which will operate the traditional service in the Strathclyde area, but also on routes to and from Perth, Alloa, Dunblane, Dundee, Leven, and between Glasgow and Edinburgh.

The new Boxing Day trains will be:

• 09:51 Arbroath to Edinburgh Waverley
• 11:35 Edinburgh Waverley to Arbroath
• 09:54 Aberdeen to Edinburgh Waverley
• 10:35 Edinburgh Waverley to Aberdeen

A normal service – with the exception of routes undergoing engineering works – will operate between Saturday, 27 December, and Tuesday, 30 December.

A revised timetable will then operate on Friday, 2 January 2026.

No trains will run between Dalmuir and Balloch/Helensburgh Central or between Glasgow Queen Street and Crianlarich between 24 December and 2 January.

This is because a new railway bridge is being installed at Bowling, West Dunbartonshire.

On those same dates, no trains will run between Motherwell and Cumbernauld via Whifflet, Bellshill and Motherwell, or between Kirkwood and Whifflet because of track upgrades in Motherwell.

Glasgow to London Euston services will be affected from 31 December until 15 January as a bridge replacement on the M6 means no trains will run between Preston and Carlisle.

West coast trains will also be affected between Christmas Day and 5 January, when there are no trains between Milton Keynes and Rugby while a worn-out junction is replaced.

Full details of all Christmas and New Year service changes, including the Boxing Day timetable, can be found on the ScotRail website and app.

Mark Ilderton, ScotRail’s service delivery director, said: “The introduction of Boxing Day services to and from Aberdeen for the first time is a real boost for customers, and we’re pleased to be offering more options for travel during one of the busiest times of the year

“Across Scotland’s railway, we’re adding extra services and more seats in the lead up to Christmas and New Year to help customers make the most of the festive season, whether they’re heading to the sales, visiting family, or enjoying a night out.

“With the removal of peak fares, travelling by train offers even better value for money over the holidays, and we’re encouraging everyone to check their journey on the ScotRail app or website before they set off.”

Customers needing assistance can speak to a member of staff at a station, use a Help Point, or get in touch via social media.

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

• Wondering if Mondelez International is a hidden gem or already fully priced? Here is a closer look at what makes this stock worth considering.

• The shares have declined 8.7% over the last year, while a modest 1.0% gain in the last week points to a potential shift in sentiment or a period of stability.

• Recent headlines have highlighted Mondelez’s strategic investments in emerging markets and ongoing sustainability initiatives, indicating that management is actively pursuing new opportunities. These developments are leading to renewed analyst interest and are helping to shape investor expectations regarding growth and long-term risk.

• According to our valuation analysis, Mondelez scores a 4 out of 6 for being undervalued. This suggests it outperforms many of its peers, though it may not be the clear bargain that some investors seek. Before relying only on traditional valuation metrics, it is useful to review the company’s strengths, areas for improvement, and smarter approaches to identifying value, which will be discussed later in this article.

Mondelez International delivered -8.7% returns over the last year. See how this stacks up to the rest of the Food industry.

A Discounted Cash Flow (DCF) model estimates the fair value of a company by projecting its future free cash flows and discounting them back to today’s dollars. This approach helps investors determine whether a stock is undervalued or overvalued based on the business’s ability to generate cash over time.

For Mondelez International, the DCF analysis uses a 2 Stage Free Cash Flow to Equity model. The company’s latest twelve months free cash flow stands at $2.31 billion. Analyst expectations suggest that free cash flow will steadily rise over the next decade, reaching $4.94 billion by the end of 2028. Further out, projections continue to show moderate growth, with discounted values indicating a consistent upward trend.

Based on these forecasts, the estimated intrinsic value for Mondelez International shares is $113.95. This represents a 49.5% discount to the current market price, signaling that the stock may be significantly undervalued according to this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Mondelez International is undervalued by 49.5%. Track this in your watchlist or portfolio, or discover 920 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Mondelez International.

The Price-to-Earnings (PE) ratio is a widely used metric for valuing companies that are solidly profitable, like Mondelez International. It tells investors how much they are paying for each dollar of earnings and is especially meaningful for established companies with strong and consistent profits.

What counts as a “normal” or “fair” PE ratio can vary. Faster-growing companies or those carrying lower risk often command higher multiples, while slower growth or greater uncertainty can bring the valuation down. Comparing these multiples to industry averages gives some context, but it is just the starting point.

Currently, Mondelez trades on a PE ratio of 21.0x, directly in line with the Food industry average of 21.0x and just above the peer group’s 20.7x. Simply Wall St’s Fair Ratio, a proprietary measure that considers factors such as Mondelez’s earnings growth, profit margins, market cap, industry trends, and company-specific risks, currently stands at 22.1x. This offers a more tailored benchmark, reducing much of the “noise” found when only comparing peers or the broad industry.

Since Mondelez’s PE ratio of 21.0x is very close to its Fair Ratio of 22.1x, the stock appears to be fairly valued based on this approach.

Result: ABOUT RIGHT

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation. Let’s introduce you to Narratives. A Narrative is an investment story that connects your expectations about a company, such as its future revenue, profit margins, and fair value, directly to its real-world outlook. Narratives allow you to explain your view on what drives Mondelez International’s value, turning raw financial numbers into a living forecast rooted in your own perspective. Narratives on Simply Wall St’s Community page make this easy and accessible for everyone, whether you are new or experienced, by providing a space for millions of investors to share and refine their outlooks.

Using Narratives, you can make clearer buy or sell decisions by instantly comparing your calculated Fair Value to today’s share price. Because these Narratives auto-update with major news, earnings, or industry changes, they stay relevant in real time. For example, one investor might expect Mondelez’s global pricing strategy and emerging market growth to support a fair value as high as $88.00, while a more cautious investor could see risks in commodity costs and set their narrative at $67.00. Narratives empower you to back up your own investment decisions with transparent, dynamic forecasts that reflect both what you believe and what is happening in the market.

Do you think there’s more to the story for Mondelez International? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MDLZ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com